Abbott Laboratories Inc.'s diabetes care business grew by over a third in the third quarter of 2019 compared to the same period of 2018 because of the continued success of the company’s FreeStyle Libre sensor-based continuous glucose monitor.
Sales of FreeStyle Libre have grown rapidly since the US Food and Drug Administration approved it in 2017, as the first continuous glucose monitor that does not require patients to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?